General form of registration statement for all companies including face-amount certificate companies

Statements of Cash Flows

v2.4.0.8
Statements of Cash Flows (USD $)
 9 Months Ended 12 Months Ended 151 Months Ended 160 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Sep. 30, 2013
Cash Flows From Operating Activities:            
Net loss $ (4,893,951) $ (5,483,954) $ (8,361,205) $ (3,444,795) $ (55,743,463) $ (60,637,414)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:            
Stock-based compensation expense 284,371 312,500 2,223,926 2,173,377 6,052,036 6,336,407
Depreciation expense    429 581 633 3,262,462 3,262,462
Loss on disposition of equipment 4,122          550,186 554,308
Amortization of debt discount    678,116 775,637 124,363 900,000 900,000
Amortization of deferred financing costs    219,725 252,248 40,444 292,692 292,692
Gain on extinguishment of liability             (260,000) (260,000)
Change in fair value derivative liabilities (216,112) 287,604 (685,420) (13,966) (699,386) (915,498)
(Increase) decrease in:            
R&D reimbursable receivable       234,088 41,567 (3,746)   
Prepaid expenses and other current assets 114,143 14,386 (18,013) 4,766 (23,397) 87,000
Increase (decrease) in:            
Accounts payable and accrued liabilities (585,043) 173,614 334,263 556,019 1,238,773 653,730
Accounts payable and accrued liabilities - related party 344,501 2,100 31,185    31,185 375,686
Net Cash Used In Operating Activities (4,947,969) (3,795,480) (5,212,710) (517,592) (44,402,658) (49,350,627)
Cash Flows From Investing Activities:            
Payment made for patent rights             (3,000,000) (3,000,000)
Purchase of property and equipment (8,030) (1,812) (2,359)    (815,659) (823,689)
Net Cash Used In Investing Activities (8,030) (1,812) (2,359)    (3,815,659) (3,823,689)
Cash Flows From Financing Activities:            
Borrowings on convertible debt, net of offering costs          645,888 645,888 645,888
Payments on note payable (140,000)             (140,000)
Sales of common stock, net of offering costs    660,163 5,129,940 5,379,367 53,191,098 53,191,098
Proceeds from the exercise of warrants for cash 3,467,393             3,467,393
Net Cash Provided By Financing Activities 3,327,393 660,163 5,129,940 6,025,255 53,836,986 57,164,379
Net change in cash (1,628,606) (3,137,129) (85,129) 5,507,663 5,618,669 3,990,063
Cash at beginning of period 5,618,669 5,703,798 5,703,798 196,135    
Cash at end of period 3,990,063 2,566,669 5,618,669 5,703,798 5,618,669 3,990,063
Supplemental disclosures of cash flow information:            
Cash paid for interest 561          682 1,243
Cash paid for taxes                  
Supplemental disclosure of non-cash investing and financing activities:            
Beneficial conversion feature discount          372,850 372,850 372,850
Fair value of warrants issued with debt          377,150 377,150 377,150
Fair value of warrants issued with stock    318,087 3,393,338 2,591,900 5,985,238 5,985,238
Fair value of warrants issued to the placement agent    159,044 658,753 1,484,529 2,170,282 2,170,282
Conversion of notes payable and accrued interest to stock       981,729    981,729 981,729
Transfer from liability classification to equity classification      $ 4,231,324   $ 4,231,324 $ 4,832,204